NITO vs BIOA

Analysts rate BioAge Labs, Inc.

(BIOA) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, BioAge Labs, Inc.

(BIOA) delivered a total return of -2. 7%, compared to -99. 8% for N2OFF, Inc. (NITO). Over 10 years, the gap is even starker: BIOA returned -2. 7% versus NITO's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioAge Labs, Inc.

(BIOA) is the lower-risk stock at 1. 41β versus N2OFF, Inc. 's 1. 61β — meaning NITO is approximately 14% more volatile than BIOA relative to the S&P 500. On balance sheet safety, BioAge Labs, Inc. (BIOA) carries a lower debt/equity ratio of 2% versus 5% for N2OFF, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: N2OFF, Inc.

grew EPS 88. 5% year-over-year, compared to 66. 2% for BioAge Labs, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

N2OFF, Inc.

(NITO) is the more profitable company, earning 0. 0% net margin versus -896. 1% for BioAge Labs, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NITO leads at 0. 0% versus -1031. 5% for BIOA. At the gross margin level — before operating expenses — BIOA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BioAge Labs, Inc.

(BIOA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. N2OFF, Inc. (NITO) carries a higher beta of 1. 61 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BIOA: -2. 7%, NITO: -99. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NITO (Basic Materials) and BIOA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.